K-07

K-07 is a novel, orally active adamantyl antiestrogen developed by the University of Illinois at Urbana-Champaign. It acts as a selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) targeting estrogen receptor alpha (ERα). K-07 is designed to overcome endocrine therapy resistance in breast cancer, demonstrating preclinical efficacy in suppressing the proliferation and metastasis of breast cancer cells driven by constitutively active mutant forms of the estrogen receptor, such as the Y537S and D538G mutations. In preclinical models, oral administration of K-07 significantly reduced metastatic burden in the liver, lungs, bone, and brain, and extended host survival.

Other names

adamantyl antiestrogen K-07compound K-07